Agreed. Gilead and Vertex have the positive news and catalysts coming throughout the year. Vertex's will be in the cystic fibrosis end. As to the small market cap Hep C company to invest in, Achillion is the one to invest in. Achillion has multiple Hep C items in the pipeline and certainly all or at least some will pan out. Also, if Achillion is not directly taken out this year I would expect some form of partnership between Achillion and other pharma such as possibly even Vertex. Of course, Gilead could get in the buying mood again and take out Achillion for $2B or less which is small change to Gilead. Gilead bought it way into the Hep C space and worked on combo Hep C package. Certainly, other companies are going to follow Gillead is working on partnering the Hep C drugs.